PepGen Q3 net loss $21.4M; cash $138.9M; DM1/DMD trial updates expected 2025

PepGen Inc.

2024-Q3 EPS reported -$2.17

Net loss of $21.4M ($0.66 per share) vs $23.3M ($0.98) in Q3 2023.
Cash and equivalents of $138.9M as of Sept 30, 2024, funding operations into 2026.
R&D expense $17.7M (down 14% YoY); G&A $5.4M (up 29% YoY).
FREEDOM-DM1 5 & 10 mg/kg data expected Q1 2025; 15 mg/kg cohort in H2 2025.
Appointed Paul Streck, MD, MBA, as EVP and Head of R&D in August 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.